Table 1. Patient characteristics at baseline by study group.
| Combination (n = 107) |
Fenofibrate (n = 52) |
Ezetimibe (n = 51) |
|
|---|---|---|---|
| Male, n (%) | 63 (58.9) | 31 (59.6) | 29 (56.9) |
| Age, years [mean ± SD] | 55.8 ± 12.6 | 58.3 ± 10.4 | 58.5 ± 10.0 |
| BMI, kg/m2 [mean ± SD] | 27.0 ± 4.4 | 25.2 ± 2.9 | 26.5 ± 3.7 |
| Medical history, n (%) | 7 (6.5) | 3 (5.8) | 4 (7.8) |
| Myocardial infarction, n (%) | 1 (0.9) | 1 (1.9) | 0 (0.0) |
| Angina, n (%) | 3 (2.8) | 3 (5.8) | 1 (2.0) |
| Stroke, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other, n (%) | 4 (3.7) | 0 (0.0) | 4 (7.8) |
| Comorbidity, n (%) | 69 (64.5) | 31 (59.6) | 30 (58.8) |
| Diabetes, n (%) | 22 (20.6) | 10 (19.2) | 10 (19.6) |
| Hypertension, n (%) | 45 (42.1) | 24 (46.2) | 25 (49.0) |
| Thyroid disease, n (%) | 4 (3.7) | 2 (3.8) | 1 (2.0) |
| Other, n (%) | 18 (16.8) | 5 (9.6) | 4 (7.8) |
| Familial combined hyperlipidemia, n (%) | 5 (4.7) | 5 (9.6) | 1 (2.0) |